TrivarX Limited (MDBIF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
TrivarX Limited (MDBIF) with AI Score 45/100 (Weak). TrivarX Limited is a health technology company focused on developing AI-driven devices for screening and diagnosing behavioral health conditions. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026TrivarX Limited (MDBIF) Healthcare & Pipeline Overview
TrivarX Limited, formerly Medibio Limited, develops AI-driven devices for behavioral health screening and diagnosis in Australia and the US. Targeting both corporate and healthcare provider markets, the company offers mental well-being solutions amidst a growing need for accessible and efficient mental health tools.
Investment Thesis
TrivarX Limited presents a focused investment opportunity within the health technology sector, specifically targeting the growing demand for AI-driven behavioral health solutions. The company's focus on both corporate and healthcare provider markets diversifies its revenue streams. Key value drivers include the successful development and commercialization of its AI-driven diagnostic devices, expansion into new geographic markets, and strategic partnerships with healthcare organizations. The company's negative P/E ratio of -1.14 and a negative profit margin of -758965.6% indicate that the company is not currently profitable, suggesting a high-risk, high-reward investment profile. Upcoming catalysts include potential regulatory approvals and product launches in the US market. Investors should closely monitor the company's cash burn rate and its ability to secure additional funding to support its growth initiatives.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.00B reflects its status as a micro-cap company with limited liquidity and higher volatility.
- P/E Ratio of -1.14 indicates the company is currently not profitable.
- Profit Margin of -758965.6% highlights significant operational challenges and high expenses relative to revenue.
- Gross Margin of -437.1% suggests the cost of goods sold exceeds revenue, requiring strategic adjustments.
- Beta of 0.46 indicates lower volatility compared to the overall market.
Competitors & Peers
Strengths
- AI-driven technology for behavioral health screening
- Scientifically validated diagnostic devices
- Presence in both Australian and US markets
- Focus on early detection and management of mental health issues
Weaknesses
- Negative profitability and high operating expenses
- Limited market capitalization and liquidity
- Reliance on regulatory approvals for market expansion
- Limited brand recognition compared to larger competitors
Catalysts
- Upcoming: Potential regulatory approvals for AI-driven diagnostic devices in the US market.
- Ongoing: Strategic partnerships with healthcare providers to expand market reach.
- Ongoing: Development and launch of new AI-driven diagnostic tools for various behavioral health conditions.
Risks
- Potential: Intense competition from established players in the healthcare information services industry.
- Potential: Regulatory hurdles and compliance requirements for medical devices.
- Potential: Technological obsolescence and the need for continuous innovation.
- Ongoing: Negative profitability and high operating expenses.
- Ongoing: Limited market capitalization and liquidity.
Growth Opportunities
- Expansion into the US Market: TrivarX has the opportunity to expand its presence in the US market, which represents a significant growth driver. The US behavioral health market is substantial, with increasing demand for innovative diagnostic tools. Successful penetration into this market, estimated to be worth billions of dollars annually, could significantly boost revenue. The timeline for this expansion depends on regulatory approvals and strategic partnerships, potentially unfolding over the next 2-3 years. A competitive advantage lies in the company's AI-driven technology, which could offer more efficient and accurate diagnostics compared to traditional methods.
- Strategic Partnerships with Healthcare Providers: Forming strategic alliances with hospitals, clinics, and other healthcare providers can accelerate the adoption of TrivarX's products. These partnerships can provide access to established patient networks and facilitate the integration of the company's solutions into existing healthcare workflows. The market for healthcare partnerships is continuously growing, with potential deals ranging from regional collaborations to national-level agreements. Securing key partnerships within the next year could significantly enhance TrivarX's market reach and credibility. The company's ability to offer customized solutions and data-driven insights can be a key differentiator in attracting these partnerships.
- Development of New AI-Driven Diagnostic Tools: TrivarX can leverage its expertise in AI to develop new diagnostic tools for a wider range of behavioral health conditions. This expansion of its product portfolio can address unmet needs in the market and attract new customer segments. The market for AI-driven diagnostics is rapidly evolving, with continuous advancements in technology and increasing demand for personalized healthcare solutions. Investing in R&D and launching new products within the next 2-3 years can position TrivarX as a leader in this space. The company's scientific approach and focus on evidence-based solutions can provide a competitive edge in developing reliable and effective diagnostic tools.
- Corporate Mental Well-being Programs: Offering mental well-being solutions for businesses represents a significant growth opportunity for TrivarX. Companies are increasingly recognizing the importance of employee mental health and are investing in programs to support their workforce. The corporate wellness market is estimated to be worth billions of dollars annually, with a growing emphasis on mental health initiatives. Expanding its corporate health product and securing contracts with large corporations within the next year can generate recurring revenue streams for TrivarX. The company's ability to provide data-driven insights and personalized solutions can be a key differentiator in attracting corporate clients.
- Geographic Expansion into Asia-Pacific: Expanding into the Asia-Pacific market presents a long-term growth opportunity for TrivarX. The region is experiencing increasing awareness of mental health issues and a growing demand for accessible and affordable solutions. The Asia-Pacific healthcare market is one of the fastest-growing in the world, with significant potential for digital health technologies. Conducting market research, establishing partnerships, and launching pilot programs within the next 3-5 years can pave the way for a successful expansion into this region. The company's ability to adapt its solutions to local needs and cultural contexts will be crucial for success in this diverse market.
Opportunities
- Expansion into new geographic markets, particularly the US
- Strategic partnerships with healthcare providers
- Development of new AI-driven diagnostic tools
- Growth in corporate mental well-being programs
Threats
- Intense competition from established players
- Regulatory hurdles and compliance requirements
- Technological obsolescence
- Economic downturn affecting healthcare spending
Competitive Advantages
- Proprietary AI-driven technology for behavioral health screening.
- Scientifically validated diagnostic devices.
- Established presence in both Australian and US markets.
- Strategic partnerships with healthcare providers.
About MDBIF
TrivarX Limited, originally incorporated in 1987 and formerly known as Medibio Limited until its name change in October 2023, is a health technology company headquartered in Mount Lawley, Australia. The company focuses on the development and commercialization of scientifically-backed, AI-driven devices designed for the screening and diagnosis of behavioral health conditions. TrivarX operates in both the Australian and United States markets, addressing the increasing need for accessible and efficient mental health solutions. The company's product offerings include mental well-being solutions tailored for businesses, marketed as a corporate health product, and specialized devices targeted towards the healthcare provider market. These solutions aim to improve the early detection and management of mental health issues, leveraging technology to enhance diagnostic accuracy and accessibility. TrivarX's strategic focus on AI and scientific validation underscores its commitment to providing reliable and innovative tools in the behavioral health space. The company aims to establish itself as a key player in the evolving landscape of digital mental healthcare.
What They Do
- Develops AI-driven devices for screening behavioral health conditions.
- Offers mental well-being solutions for businesses.
- Creates products for the healthcare provider market.
- Focuses on early detection and management of mental health issues.
- Leverages technology to enhance diagnostic accuracy.
- Operates in Australia and the United States.
Business Model
- Develops and sells AI-driven diagnostic devices.
- Offers subscription-based mental well-being programs for businesses.
- Generates revenue through direct sales to healthcare providers.
- Forms strategic partnerships for distribution and market access.
Industry Context
TrivarX Limited operates within the healthcare information services industry, a segment experiencing rapid growth due to increasing adoption of digital health technologies and rising awareness of mental health issues. The market is characterized by intense competition, with players like AIMLF (CloudMD Software & Services Inc.), CMHSF (CareRx Corporation), and others vying for market share. The industry is driven by the need for more efficient and accessible healthcare solutions, particularly in behavioral health. TrivarX's focus on AI-driven diagnostics positions it to capitalize on these trends, but it must navigate regulatory hurdles and competitive pressures to succeed.
Key Customers
- Businesses seeking to improve employee mental well-being.
- Hospitals and clinics needing advanced diagnostic tools.
- Healthcare providers focused on early detection of mental health issues.
- Individuals seeking accessible mental health screening.
Financials
Chart & Info
TrivarX Limited (MDBIF) stock price: Price data unavailable
Latest News
No recent news available for MDBIF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MDBIF.
Price Targets
Wall Street price target analysis for MDBIF.
MoonshotScore
What does this score mean?
The MoonshotScore rates MDBIF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Kai Sun
CEO
Kai Sun serves as the Chief Executive Officer of TrivarX Limited. Information regarding Kai Sun's detailed career history, educational background, and previous roles is not available in the provided data. Further research would be needed to provide a comprehensive profile of Mr. Sun's professional background and qualifications.
Track Record: Due to limited information, a detailed track record of Kai Sun's achievements, strategic decisions, and company milestones under their leadership cannot be accurately assessed. Further information is needed to evaluate their performance and impact on TrivarX Limited.
MDBIF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that TrivarX Limited may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not provide regular financial disclosures. Investing in OTC Other stocks carries significant risks compared to stocks listed on major exchanges like the NYSE or NASDAQ, due to the potential for less transparency and greater price volatility.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry.
- Low trading volume can lead to significant price volatility.
- Higher potential for fraud and manipulation compared to listed exchanges.
- OTC Other status indicates the company may not meet minimum financial standards.
- Illiquidity can make it difficult to exit positions.
- Verify the company's financial statements and audit reports.
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and legal risks.
- Monitor trading volume and price volatility.
- Understand the company's capital structure and funding needs.
- Company was incorporated in 1987, indicating a long operating history.
- Focus on AI-driven technology and scientific validation suggests a commitment to innovation.
- Operations in both Australia and the United States demonstrate international reach.
- Development of products for both corporate and healthcare provider markets diversifies revenue streams.
MDBIF Healthcare Stock FAQ
What does TrivarX Limited do?
TrivarX Limited is a health technology company specializing in the development and commercialization of AI-driven devices for the screening and diagnosis of behavioral health conditions. The company offers mental well-being solutions for businesses through its corporate health product and develops products for the healthcare provider market. By focusing on early detection and management of mental health issues, TrivarX aims to improve diagnostic accuracy and accessibility in both Australia and the United States, leveraging technology to address the growing need for efficient and reliable mental healthcare solutions.
What do analysts say about MDBIF stock?
Given that AI analysis is pending for MDBIF, there is no current analyst consensus available. Key valuation metrics such as the negative P/E ratio and profit margin suggest that the company is not yet profitable and may be considered a high-risk investment. Growth considerations include the successful commercialization of its AI-driven diagnostic devices and expansion into new markets. Investors should conduct their own due diligence and carefully evaluate the company's financial performance and growth prospects before making any investment decisions.
What are the main risks for MDBIF?
The main risks for TrivarX Limited include intense competition from established players in the healthcare information services industry, regulatory hurdles and compliance requirements for medical devices, and the potential for technological obsolescence. The company's negative profitability and high operating expenses also pose significant financial risks. Additionally, its limited market capitalization and liquidity could lead to price volatility and difficulty in exiting positions. Investors should carefully consider these risks before investing in MDBIF.
What are the key factors to evaluate for MDBIF?
TrivarX Limited (MDBIF) currently holds an AI score of 45/100, indicating low score. Key strength: AI-driven technology for behavioral health screening. Primary risk to monitor: Potential: Intense competition from established players in the healthcare information services industry.. This is not financial advice.
How frequently does MDBIF data refresh on this page?
MDBIF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven MDBIF's recent stock price performance?
Recent price movement in TrivarX Limited (MDBIF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: AI-driven technology for behavioral health screening. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider MDBIF overvalued or undervalued right now?
Determining whether TrivarX Limited (MDBIF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying MDBIF?
Before investing in TrivarX Limited (MDBIF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available for comprehensive analysis.
- OTC market investments carry higher risks.
- AI analysis pending for MDBIF.